Predict your next investment

HemoShear Therapeutics company logo
HEALTHCARE | Drug Discovery
hemoshear.com

See what CB Insights has to offer

Competitors

12

Business Relationships

10

HemoShear Therapeutics Competitors & Alternatives

12 Competitors

HemoShear Therapeutics has 12 competitors. HemoShear Therapeutics's competitors are SynCardia Systems, Bioness, FzioMed, Mercator MedSystems, Elastagen and more.

Latest Funding

Companies

Investment Stage

Total Funding

Mosaic
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

Location

9/30/2021

Acquired

$56.53M

Arizona

3/31/2021

Acquired

$3.5M

California

5/1/2020

Loan

$7.42M

California

4/13/2020

Loan

$23.33M

California

2/7/2018

Acquired

$21.59M

Australia

9/21/2010

FluimediX

Seed VC

$1.1M

Denmark

8/17/2010

Osteotech

Acq - P2P

New Jersey

4/10/2010

Tengion

IPO

$143M

North Carolina

12/14/2009

Optonol

Acquired

$1.5M

Switzerland

4/16/2007

Ifc Medical

Unattributed VC

$8.5M

Minnesota

Latest Funding

9/30/2021

3/31/2021

5/1/2020

4/13/2020

2/7/2018

9/21/2010

8/17/2010

4/10/2010

12/14/2009

4/16/2007

Companies

FluimediX

Osteotech

Tengion

Optonol

Ifc Medical

Investment Stage

Acquired

Acquired

Loan

Loan

Acquired

Seed VC

Acq - P2P

IPO

Acquired

Unattributed VC

Total Funding

$56.53M

$3.5M

$7.42M

$23.33M

$21.59M

$1.1M

$143M

$1.5M

$8.5M

Mosaic

Location

Arizona

California

California

California

Australia

Denmark

New Jersey

North Carolina

Switzerland

Minnesota

HemoShear Therapeutics Partners & Customers

10 Partners and customers

HemoShear Therapeutics has 10 strategic partners and customers. HemoShear Therapeutics recently partnered with Horizon Therapeutics on April 4, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

4/21/2021

Licensee

Horizon Therapeutics

Ireland

HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout

Charlottesville , VA> -- April 21 , 2021 -- HemoShear Therapeutics , Inc. , a privately held clinical stage biotechnology company , has identified a second drug target for the treatment of gout under its collaboration with Horizon Therapeutics plc that was established in January 2019 .

2

12/10/2020

Licensee

Takeda Pharmaceutical

Japan

HemoShear Therapeutics Identifies Novel Drug Target to Treat NASH in Drug Discovery Partnership with Takeda

CHARLOTTESVILLE , Va. , Dec. 10 , 2020 / PRNewswire / -- HemoShear Therapeutics , LLC , a privately held clinical stage biotechnology company , has achieved a research milestone in its discovery and development collaboration with Takeda Pharmaceutical Company Limited to advance its first nonalcoholic steatohepatitis target into Takeda Pharmaceutical Company Limited 's discovery portfolio .

2

10/21/2020

Licensee

Takeda Pharmaceutical

Japan

HemoShear Therapeutics Enters into Rare Liver Disease Research Collaboration with Takeda

`` We have identified and validated innovative targets through our existing partnership with HemoShear Therapeutics that we continue to explore in early research , '' said Gareth Hicks , Ph.D. , GI Drug Discovery Unit Head at Takeda Pharmaceutical Company Limited .

1

3/20/2019

Partner

Takeda Pharmaceutical

Japan

Subscribe to see more

Subscribe to see more

10

1/3/2019

Partner

Horizon Therapeutics

Ireland

Subscribe to see more

Subscribe to see more

10

Date

4/21/2021

12/10/2020

10/21/2020

3/20/2019

1/3/2019

Type

Licensee

Licensee

Licensee

Partner

Partner

Business Partner

Horizon Therapeutics

Takeda Pharmaceutical

Takeda Pharmaceutical

Takeda Pharmaceutical

Horizon Therapeutics

Country

Ireland

Japan

Japan

Japan

Ireland

News Snippet

HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout

Charlottesville , VA> -- April 21 , 2021 -- HemoShear Therapeutics , Inc. , a privately held clinical stage biotechnology company , has identified a second drug target for the treatment of gout under its collaboration with Horizon Therapeutics plc that was established in January 2019 .

HemoShear Therapeutics Identifies Novel Drug Target to Treat NASH in Drug Discovery Partnership with Takeda

CHARLOTTESVILLE , Va. , Dec. 10 , 2020 / PRNewswire / -- HemoShear Therapeutics , LLC , a privately held clinical stage biotechnology company , has achieved a research milestone in its discovery and development collaboration with Takeda Pharmaceutical Company Limited to advance its first nonalcoholic steatohepatitis target into Takeda Pharmaceutical Company Limited 's discovery portfolio .

HemoShear Therapeutics Enters into Rare Liver Disease Research Collaboration with Takeda

`` We have identified and validated innovative targets through our existing partnership with HemoShear Therapeutics that we continue to explore in early research , '' said Gareth Hicks , Ph.D. , GI Drug Discovery Unit Head at Takeda Pharmaceutical Company Limited .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

2

1

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.